the farnesyltransferase inhibitor sch-66336 shows evidence of clinical activity,

Download The farnesyltransferase inhibitor SCH-66336 shows evidence of clinical activity,

Post on 13-Dec-2016




0 download

Embed Size (px)


  • Inpharma 1238 - 20 May 2000

    The farnesyltransferase inhibitor SCH-66336*shows evidence of clinical activity, report researchersfrom the US. In this study, 20 patients with metastaticor locally advanced solid tumours received oralSCH-66336 25400mg twice daily for 7 days of each21-day cycle. The median number of cyclesadministered was 2.5. The maximum tolerated dosagewas found to be 350mg twice daily. A partial responsewas achieved after 2 courses of therapy in 1 patientwho had non-small-cell lung cancer. Eight patientsexperienced disease stabilisation for 510 cycles. Theresearchers say that their study provides the firstevidence of clinical activity of this class of agents.* Schering-Plough; phase II in pancreatic cancer and solid tumours

    Adjei AA, et al. A phase I trial of the farnesyl transferase inhibitor SCH66336:evidence for biological and clinical activity. Cancer Research 60: 1871-1877, 1Apr 2000 800825542


    Inpharma 20 May 2000 No. 12381173-8324/10/1238-0001/$14.95 Adis 2010 Springer International Publishing AG. All rights reserved